Mapping the Mind: How Different Therapies Tackle Suicidal Thoughts

Suicidal ideation (SI) remains a critical risk factor, yet many current treatments were not designed specifically to target it. A recent systematic review of twenty-four studies has shed light on the neurophysiological biomarkers—measurable indicators of brain activity—that underpin successful interventions.

The research highlights a distinct contrast between therapies. Intravenous (IV) ketamine, known for its rapid anti-suicidal effects, appears to modulate the anterior cingulate cortex (ACC). notably, oral ketamine does not show this same ACC engagement, which may explain why it is clinically less effective than the IV method. Conversely, seizure-based interventions, such as electroconvulsive therapy and magnetic seizure therapy, seem to target the prefrontal cortex (PFC).

The authors suggest a functional separation: ACC activity may be linked to acute, transient relief, whereas PFC modulation could drive the sustained recovery seen in seizure therapies. Despite limitations in the current data, such as study heterogeneity, identifying these specific neural targets is a vital step towards optimising future treatments for patients.